Hypofractionated Radiotherapy for Stage I Squamous Cell Carcinoma Glottis: An Experience with 60Gy in 20 Fractions

Document Type : Original Paper

Authors

1 Department of Radiation Oncology, Amrita School of Medicine, Amrita Institute of Medical Sciences and Research, Amrita Vishwa Vidyapeetham, AIMS, Ponekkara P.O., Kochi, Kerala, Pin Code 682041

2 Department of Radiation Oncology, Amrita School of Medicine, Amrita Institute of Medical Sciences and Research, Amrita Vishwa Vidyapeetham, AIMS, Ponekkara P.O., Kochi, Kerala, Pin Code 682041.

3 Department of Head and Neck Surgery and Oncology, Amrita School of Medicine, Amrita Institute of Medical Sciences and Research, Amrita Vishwa Vidyapeetham, AIMS, Ponekkara P.O., Kochi, Kerala, Pin Code 682041

4 Department of Biostatistics, Amrita School of Medicine, Amrita Institute of Medical Sciences and Research, Amrita Vishwa Vidyapeetham, AIMS, Ponekkara P.O., Kochi, Kerala, Pin Code 682041

Abstract

Introduction: Early-stage glottic cancer has a high cure rate with definitive radiotherapy. Historical reports show excellent local control. The present study evaluated the outcomes of early glottic cancer patients treated with a hypofractionated radiotherapy schedule of 60Gy in 20 fractions.
Material and Methods: This is a retrospective study of patients with stage I glottic cancer who received radical intent LINAC-based hypo-fractionated 3D conformal radiotherapy with a dose 60Gy in 20 fractions. The primary objective was to assess the locoregional control (LRC), and secondary objectives were to determine disease-free survival (DFS), overall survival (OS), and toxicity.
Results: The analysis included 105 patients from the age range of 35-88 years. About 69% of patients were over 60 years of age. The median overall treatment time (OTT) was 26 days (24 – 30 days). The mean follow-up was 74 months, ranging from 9 to 135 months. Seven patients had locoregional recurrence after an initial complete clinical response. Six had local, and one had a regional nodal recurrence. DFS at five years and ten years were 83% and 69%, and OS at five years and ten years were 87% and 80%, respectively. Most patients reported grade I skin reactions and tolerated the treatment well. We did not observe any late adverse events such as persistent laryngeal edema or radiation necrosis.
Conclusion: The radiotherapy schedule of 60Gy in 20 fractions over four weeks offers comparable local disease control with reasonable long-term side effects in T1 glottic cancer.

Keywords

Main Subjects

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-49. DOI: 10.3322/caac.21660.
  2. Mendenhall WM, Werning JW, Hinerman RW, Amdur RJ, Villaret DB. Management of T1-T2 glottic carcinomas. Cancer. 2004 May 1;100(9):1786-92. DOI: 10.1002/cncr.20181.
  3. Fein DA, Mendenhall WM, Parsons JT, Million RR. T1-T2 squamous cell carcinoma of the glottic larynx treated with radiotherapy: a multivariate analysis of variables potentially influencing local control. Int J Radiat Oncol Biol Phys. 1993 Mar 15;25(4):605-11. DOI: 10.1016/0360-3016(93)90005-g.
  4. Gowda RV, Henk JM, Mais KL, Sykes AJ, Swindell R, Slevin NJ. Three weeks radiotherapy for T1 glottic cancer: the Christie and Royal Marsden Hospital Experience. Radiother Oncol. 2003 Aug;68(2):105-11. DOI: 10.1016/s0167-8140(03)00059-8.
  5. Schwaibold F, Scariato A, Nunno M, Wallner PE, Lustig RA, Rouby E, et al. The effect of fraction size on control of early glottic cancer. Int J Radiat Oncol Biol Phys. 1988 Mar;14(3):451-4. DOI: 10.1016/0360-3016(88)90259-3.
  6. Le QT, Fu KK, Kroll S, Ryu JK, Quivey JM, Meyler TS, et al. Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. Int J Radiat Oncol Biol Phys. 1997 Aug 1;39(1):115-26. DOI: 10.1016/s0360-3016(97)00284-8.
  7. Mendenhall WM, Parsons JT, Million RR, Fletcher GH. T1-T2 squamous cell carcinoma of the glottic larynx treated with radiation therapy: relationship of dose-fractionation factors to local control and complications. Int J Radiat Oncol Biol Phys. 1988 Dec;15(6):1267-73. DOI: 10.1016/0360-3016(88)90220-9.
  8. Aaltonen LM, Rautiainen N, Sellman J, Saarilahti K, Mäkitie A, Rihkanen H, et al. Voice quality after treatment of early vocal cord cancer: a randomized trial comparing laser surgery with radiation therapy. Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):255-60. DOI: 10.1016/j.ijrobp.2014.06.032.
  9. Pakkanen P, Irjala H, Ilmarinen T, Halme E, Lindholm P, Mäkitie A, et al. Survival and Larynx Preservation in Early Glottic Cancer: A Randomized Trial Comparing Laser Surgery and Radiation Therapy. International Journal of Radiation Oncology* Biology* Physics. 2022 May 1;113(1):96-100.
  10. Vaculik MF, MacKay CA, Taylor SM, Trites JR, Hart RD, Rigby MH. Systematic review and meta-analysis of T1 glottic cancer outcomes comparing CO2 transoral laser microsurgery and radiotherapy. Journal of Otolaryngology-Head & Neck Surgery. 2019 Dec;48(1):1-1.
  11. Smee RI, Meagher NS, Williams JR, Broadley K, Bridger GP. Role of radiotherapy in early glottic carcinoma. Head Neck. 2010 Jul;32(7):850-9. DOI: 10.1002/hed.21262.
  12. Bhattacharyya T, Kainickal CT. Current Status of Organ Preservation in Carcinoma Larynx. World J Oncol. 2018 Apr;9(2):39-45. DOI: 10.14740/wjon1105w.
  13. Laskar SG, Baijal G, Murthy V, Chilukuri S, Budrukkar A, Gupta T, et al. Hypofractionated radiotherapy for T1N0M0 glottic cancer: retrospective analysis of two different cohorts of dose-fractionation schedules from a single institution. Clin Oncol (R Coll Radiol). 2012 Dec;24(10):e180-6. DOI: 10.1016/j.clon.2012.07.001.
  14. Ermiş E, Teo M, Dyker KE, Fosker C, Sen M, Prestwich RJ. Definitive hypofractionated radiotherapy for early glottic carcinoma: experience of 55Gy in 20 fractions. Radiat Oncol. 2015 Sep 23;10:203. DOI: 10.1186/s13014-015-0505-6.
  15. Karasawa K, Kunogi H, Hirai T, Hoji H, Hirowatari H, Izawa H, et al. Radiotherapy with fraction size of 2.25 Gy in T1-2 laryngeal and hypopharyngeal cancer. J Radiat Res. 2013 Jul 1;54(4):684-9. DOI: 10.1093/jrr/rrs134.
  16. Ridge JA, Lawson J, Yom SS, Garg MK, McDonald MW, Quon H, et al. American College of Radiology Appropriateness Criteria(®) treatment of stage I T1 glottic cancer. Head Neck. 2014 Jan;36(1):3-8. DOI: 10.1002/hed.23381.
  17. Nishimura Y, Nagata Y, Okajima K, Mitsumori M, Hiraoka M, Masunaga S, et al. Radiation therapy for T1,2 glottic carcinoma: impact of overall treatment time on local control. Radiother Oncol. 1996 Sep;40(3):225-32. DOI: 10.1016/0167-8140(96)01796-3.
  18. Onimaru R, Hasegawa M, Yasuda K, Homma A, Oridate N, Fukuda S, et al. Radiotherapy for glottic T1N0 carcinoma with slight hypofractionation and standard overall treatment time: importance of overall treatment time. Jpn J Clin Oncol. 2011 Jan;41(1):103-9. DOI: 10.1093/jjco/hyq153.
  19. Lee JW, Lee JE, Park J, Sohn JH, Ahn D. Hypofractionated radiotherapy for early glottic cancer: a retrospective interim analysis of a single institution. Radiat Oncol J. 2019 Jun;37(2):82-90. DOI: 10.3857/roj.2019.00143.
  20. Fowler JF. Fractionation and glottic carcinoma. Int J Radiat Oncol Biol Phys. 1997 Aug 1;39(1):1-2. DOI: 10.1016/s0360-3016(97)00445-8.
  21. Yamazaki H, Nishiyama K, Tanaka E, Koizumi M, Chatani M. Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):77-82. DOI: 10.1016/j.ijrobp.2005.06.014.
  22. Moon SH, Cho KH, Chung EJ, Lee CG, Lee KC, Chai GY, et al. A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1-2 glottic squamous cell carcinomas: results of a Korean Radiation Oncology Group KROG-0201) study. Radiother Oncol. 2014 Jan;110(1):98-103. DOI: 10.1016/j.radonc.2013.09.016.
  23. Cheah NL, Lupton S, Marshall A, Hartley A, Glaholm J. Outcome of T1N0M0 squamous cell carcinoma of the larynx treated with short-course radiotherapy to a total dose of 50 Gy in 16 fractions: the Birmingham experience. Clin Oncol (R Coll Radiol). 2009 Aug;21(6):494-501. DOI: 10.1016/j.clon.2009.02.008.
  24. Mendenhall WM, Amdur RJ, Morris CG, Hinerman RW. T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol. 2001 Oct 15;19(20):4029-36. DOI: 10.1200/JCO.2001.19.20.4029.
  25. Zouhair A, Azria D, Coucke P, Matzinger O, Bron L, Moeckli R, et al. Decreased local control following radiation therapy alone in early-stage glottic carcinoma with anterior commissure extension. StrahlentherOnkol. 2004 Feb;180(2):84-90. DOI: 10.1007/s00066-004-1164-y.

 

 

 

 

 

 

Iranian Journal of Medical Physics
Volume 20, Issue 4
July and August 2023
Pages 226-232

Files

History

  • Receive Date: 25 January 2022
  • Revise Date: 06 August 2022
  • Accept Date: 14 August 2022

Share

How to cite

Statistics